阿里健康(00241.HK)涉虛假宣傳被罰45萬人幣
阿里健康(00241.HK)旗下阿里健康大藥房因違反廣告法,被廣州市黃埔區市場監督管理局罰款45萬元人民幣。
處罰事由顯示,當事人在「阿里健康大藥房」發布的「黃金搭檔萌之虎牌鈣鐵鋅口服液」等保健食品、藥品及醫療器材廣告未經廣告機關審查、發布的「王老吉膠原蛋白雪蓮飲」等一般食品的宣傳廣告存在以虛假或引人誤解的內容欺騙、誤導消費者的情形,發布的「北京同仁堂牡蠣片壓片糖果」等一般食品及「白雲山眼部護理液」的宣傳廣告涉及疾病治療功能、發布的處方藥「常藥葉酸片」的宣傳廣告,發布地點為非國務院衛生行政部門和國務院藥品監督管理部門共同指定的醫學、藥學專業刊物上。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.